HOIP for targeting diffuse large B-cell lymphoma

Joel L. Pomerantz

doi:10.1182/BLOOD.2020006242

HOIP for targeting diffuse large B-cell lymphoma

Joel L. Pomerantz

School of Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

In this issue of Blood, Jo et al¹ provide compelling evidence in a mouse model that enhanced activity of the linear ubiquitin chain assembly complex (LUBAC) can drive B-cell lymphomagenesis and may offer a new therapeutic target for the activated B-cell–like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL).

Original language	English (US)
Pages (from-to)	646-647
Number of pages	2
Journal	Blood
Volume	136
Issue number	6
DOIs	https://doi.org/10.1182/BLOOD.2020006242
State	Published - Aug 2020

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/BLOOD.2020006242

Fingerprint Dive into the research topics of 'HOIP for targeting diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

Cite this

@article{f50b73fee74e4571a2a3243ba397915d,

title = "HOIP for targeting diffuse large B-cell lymphoma",

abstract = "In this issue of Blood, Jo et al1 provide compelling evidence in a mouse model that enhanced activity of the linear ubiquitin chain assembly complex (LUBAC) can drive B-cell lymphomagenesis and may offer a new therapeutic target for the activated B-cell–like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL).",

author = "Pomerantz, {Joel L.}",

year = "2020",

month = aug,

doi = "10.1182/BLOOD.2020006242",

language = "English (US)",

volume = "136",

pages = "646--647",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "6",

}

TY - JOUR

T1 - HOIP for targeting diffuse large B-cell lymphoma

AU - Pomerantz, Joel L.

PY - 2020/8

Y1 - 2020/8

N2 - In this issue of Blood, Jo et al1 provide compelling evidence in a mouse model that enhanced activity of the linear ubiquitin chain assembly complex (LUBAC) can drive B-cell lymphomagenesis and may offer a new therapeutic target for the activated B-cell–like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL).

AB - In this issue of Blood, Jo et al1 provide compelling evidence in a mouse model that enhanced activity of the linear ubiquitin chain assembly complex (LUBAC) can drive B-cell lymphomagenesis and may offer a new therapeutic target for the activated B-cell–like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL).

UR - http://www.scopus.com/inward/record.url?scp=85089170843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089170843&partnerID=8YFLogxK

U2 - 10.1182/BLOOD.2020006242

DO - 10.1182/BLOOD.2020006242

M3 - Review article

C2 - 32761216

AN - SCOPUS:85089170843

VL - 136

SP - 646

EP - 647

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -